Max Nisen, Columnist

Valeant's Defense Is All Noise, No Substance

Instead of complaining about coverage, it should meet promises.

December 15, 2016 at 6:44 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

According to Valeant CEO Joe Papa, speaking at a BMO health care conference on Wednesday, the company's biggest problem is click-hungry journalists writing negative articles, which he characterized as "noise."

And there I was, thinking it was the continued decay of the specialty pharmaceutical firm's business in the shadow of a $30 billion debt load, a biblical list of pending lawsuits and investigations, and a near-complete lack of tangible evidence of improvement.